Current status of immunotherapy for non-small cell lung cancer
T Yang, Y Xiong, Y Zeng, Y Wang, J Zeng… - Frontiers in …, 2022 - frontiersin.org
Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them,
non-small cell lung cancer (NSCLC) accounts for 80%∼ 85% of all lung cancers, and its 5 …
non-small cell lung cancer (NSCLC) accounts for 80%∼ 85% of all lung cancers, and its 5 …
Discovery, development, inventions, and patent trends on mobocertinib succinate: The first-in-class oral treatment for NSCLC with EGFR exon 20 insertions
The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival
rate. Recent studies have indicated the involvement of epidermal growth factor receptor …
rate. Recent studies have indicated the involvement of epidermal growth factor receptor …
Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice
Plasma-based next-generation sequencing (NGS) has demonstrated the potential to guide
the personalized treatment of non-small cell lung cancer (NSCLC). Inherent differences in …
the personalized treatment of non-small cell lung cancer (NSCLC). Inherent differences in …
Comparison between three different techniques for the detection of EGFR mutations in liquid biopsies of patients with advanced stage lung adenocarcinoma
M Casula, M Pisano, P Paliogiannis… - International Journal of …, 2023 - mdpi.com
Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors (TKIs) in
lung adenocarcinoma (LC) patients, and their search is mandatory to make decisions on …
lung adenocarcinoma (LC) patients, and their search is mandatory to make decisions on …
Nephrotoxicity of targeted therapy used to treat lung cancer
Q Li, J Lin, G Hao, A Xie, S Liu, B Tang - Frontiers in Immunology, 2024 - frontiersin.org
Lung cancer is the leading cause of cancer-related death worldwide, especially non-small
cell lung cancer. Early diagnosis and better treatment choices have already provided a more …
cell lung cancer. Early diagnosis and better treatment choices have already provided a more …
Comprehensive analysis of acetylation‐related lncRNAs and identified AC099850. 3 as prognostic biomarker in non‐small cell lung cancer
J Zhou, M Zhang, H Dong, M Wang… - Journal of …, 2021 - Wiley Online Library
The present study aimed to analyze the effects of acetylation‐related lncRNAs in non‐small‐
cell lung cancer (NSCLC). A total of 399 differentially expressed lncRNAs (DElncRNAs) …
cell lung cancer (NSCLC). A total of 399 differentially expressed lncRNAs (DElncRNAs) …
Elucidation of the inhibitory potential of flavonoids against PKP1 protein in non-small cell lung cancer
PKP1 has been crucially involved in enhancing the MYC translation leading to lung
carcinogenesis via evading numerous tumour-suppressing checkpoint systems. Plakophilin …
carcinogenesis via evading numerous tumour-suppressing checkpoint systems. Plakophilin …
PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer
S Zhao, Y Li, G Li, J Ye, R Wang, X Zhang, F Li… - European Journal of …, 2023 - Elsevier
Small molecule drugs are of significant importance in the treatment of non-small cell lung
cancer (NSCLC). Here, we explored biological effects of the PI3K/mTOR inhibitor VS-5584 …
cancer (NSCLC). Here, we explored biological effects of the PI3K/mTOR inhibitor VS-5584 …
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer …
K Park, JS Kim, JH Kim, YC Kim, HG Kim, EK Cho… - BMC cancer, 2021 - Springer
Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
[HTML][HTML] Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Background Afatinib can be started at a dose lower than the recommended starting dose of
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …